A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

MLA

Max E. Scheulen, et al. “A Randomised, Double-Blind, Placebo-Controlled Trial of Trametinib, an Oral MEK Inhibitor, in Combination with Gemcitabine for Patients with Untreated Metastatic Adenocarcinoma of the Pancreas.” European Journal of Cancer (Oxford, England : 1990), vol. 50, no. 12, Dec. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d544a6b63799615777921b384ed3118f&authtype=sso&custid=ns315887.

APA

Max E. Scheulen, Chung-Pin Li, Ngocdiep Le, Joon Oh Park, Yuan Liu, Klaudia Steplewski, Saifuddin M. Kasubhai, Do-Youn Oh, Jeffrey R. Infante, Bradley G. Somer, & Suman Redhu. (2013). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer (Oxford, England : 1990), 50(12).

Chicago

Max E. Scheulen, Chung-Pin Li, Ngocdiep Le, Joon Oh Park, Yuan Liu, Klaudia Steplewski, Saifuddin M. Kasubhai, et al. 2013. “A Randomised, Double-Blind, Placebo-Controlled Trial of Trametinib, an Oral MEK Inhibitor, in Combination with Gemcitabine for Patients with Untreated Metastatic Adenocarcinoma of the Pancreas.” European Journal of Cancer (Oxford, England : 1990) 50 (12). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d544a6b63799615777921b384ed3118f&authtype=sso&custid=ns315887.